A new AI tool developed by Mass General Brigham has identified long COVID in 22.8% of patients, much higher than previous 7% estimates. The tool analyses health records from nearly 300,000 patients, using 'precision phenotyping' to distinguish long COVID symptoms from pre-existing conditions. It improves diagnostic accuracy and addresses demographic biases. Researchers plan to release the algorithm publicly for global use, potentially advancing research on long COVID subtypes.
A major AI-ready dataset on type 2 diabetes has been released, containing diverse data from over 1,000 participants. The AI-READI study aims to collect data from 4,000 people for global analysis. The dataset is accessible through an online platform and has already been downloaded by numerous research organisations worldwide. Multiple institutions are involved in this project, based in Seattle.
